tradingkey.logo
搜索

BioLife Solutions Inc

BLFS
添加自选
28.110USD
-0.380-1.33%
收盘 07/02, 13:00美东报价延迟15分钟
1.37B总市值
亏损市盈率 TTM

BioLife Solutions Inc

28.110
-0.380-1.33%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.33%

5天

-1.95%

1月

+3.77%

6月

+17.66%

今年开始到现在

+16.25%

1年

+23.07%

关键数据
28.790今开
28.910最高
655.34K成交量
亏损市盈率 TTM
81.75市盈率动
--股息TTM
1.34%换手率
28.490昨收
28.030最低
13.30M成交额
亏损市盈率静
3.69市净率
0.00%股息率 TTM
-2.82%ROA
29.62052周最高
0.55量比
-20.18M净利润
48.83M总股本
-0.0622每股收益TTM
2.00Beta
-3.09%ROE
17.86052周最低
3.09%振幅
63.31%毛利率
1.37B总市值
1.96回报/风险
2.63%风险率

TradingKey BioLife Solutions Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

BioLife Solutions Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名23/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价32.11。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

BioLife Solutions Inc评分

相关信息

行业排名
23 / 204
全市场排名
77 / 4565
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

BioLife Solutions Inc亮点

亮点风险
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
业绩高增长
公司营业收入稳步增长,连续3年增长26.84%
业绩增长期
公司处于发展阶段,最新年度总收入96.21M美元
估值低估
公司最新PE估值-451.57,处于3年历史低位
机构减仓
最新机构持股51.34M股,环比减少2.40%
活跃度增加
近期活跃度增加,过去20天平均换手率1.41

分析师目标

根据 9 位分析师
买入
评级
32.111
目标均价
+12.71%
涨幅空间

BioLife Solutions Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

BioLife Solutions Inc简介

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
公司代码BLFS
公司BioLife Solutions Inc
CEODe Greef (Roderick)
网址https://www.biolifesolutions.com/

常见问题

BioLife Solutions Inc(BLFS)的当前股价是多少?

BioLife Solutions Inc(BLFS)的当前股价是 28.11。

BioLife Solutions Inc的股票代码是什么?

BioLife Solutions Inc的股票代码是BLFS。

BioLife Solutions Inc股票的52周最高点是多少?

BioLife Solutions Inc股票的52周最高点是29.62。

BioLife Solutions Inc股票的52周最低点是多少?

BioLife Solutions Inc股票的52周最低点是17.86。

BioLife Solutions Inc的市值是多少?

BioLife Solutions Inc的市值是1.35B。

现在BioLife Solutions Inc(BLFS)的股票是买入、持有还是卖出?

根据分析师评级,BioLife Solutions Inc(BLFS)的总体评级为买入,目标价格为32.11。

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是多少

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是-0.10。